Breast Cancer in Young Women under 40 years: Epidemiological, Clinical, Therapeutic and Prognostic Aspects in the Oncology and Radiotherapy Department of Marrakech; About 318 Cases


Département de Radiothérapie, CHU Mohammed VI, Marrakech

Abstract

Introduction: Breast cancer in women, and especially in young women, represents a real public health issue given its frequency and severity. The objective of our study is to specify the epidemiological profile; anatomo-clinical; therapy and prognosis of breast cancer in young women. Methods: Descriptive retrospective study spread over a period of 5 years (2013-2017), collecting all the patients followed for breast cancer aged 40 years or less, within the cancer department of CHU Med VI in Marrakech. Results: The average age was 34.2 years (19-40 years). The average age at puberty was 12 years old (9 and 16 years old). Nulliparity was noted in 22% of the cases. Clinically, the T classification in the cases specified was: T1 (n = 48), T2 (n = 128), T3 (n = 52), T4 (n = 42). Clinical lymph node involvement was found in 44% of the cases. Histologically, infiltrating ductal carcinoma was the most common (n = 283). SBR II grade was the most frequent with a rate of 66%. Thirty Fifty percent of all patients had an over-expression of HER2, Sixty-three percent had lymph node invasion, including 42% with capsular rupture and 31% of patients were metastatic in appearance. Therapeutically, fifty patients had neo-adjuvant chemotherapy. The surgery was conservative in 66% of the cases. Adjuvant chemotherapy was sequential in 61% of the cases. 180 patients had adjuvant radiation therapy. Of the 96 patients with HER2 over expression, 82 received treatment with trastuzumab. Hormone therapy was prescribed in 156 patients or 49% of cases with expression of hormone receptors. In our series, the median follow-up was 8.1 months. The course was marked by a locoregional relapse in fifty-eight patients, and a metastatic relapse in sixty patients. Conclusion: Since screening in our country does not include young women, it would be interesting to reconsider its indications, especially given the growing frequency of this cancer in young women as well as its poor prognosis. Keywords: Breast cancer / young woman / prognostic factors / treatment.
PATIENTS AND METHODS
This is a descriptive retrospective epidemiological study, covering 318 cases of breast cancer in women under 40, collecting all patients followed for breast cancer aged 40 or less, within the service of oncology of CHU Med VI Marrakech, over a period of 5 years (2013-2017).

Clinical information was collected from clinical and technical patient files using an exploitation sheet. The study variants selected were age, personal and family history, consultation time, clinical characteristics and paraclinical, histological examination of the part and extension assessment. Thus all the patients were stratified according to the TNM classification.

The pre-therapeutic assessment included an interrogation, a clinical examination, an echomammography, a chest radiography, an abdominal ultrasound, a thoraco-abdomino-pelvin CT, a bone scan and sometimes a CA-15-3 assay. The hormone receptors (RH), the research proto-oncogene HER-2 / neu, and the histopronostic grade of Scarff-BloomRichardson (SBR), were specified in all the patients.

The management of these patients is validated during a multidisciplinary concertation meeting bringing together a gyneco obstetrician, an oncologist, a radiotherapist.

For operable non-metastatic tumors of size less than 3 cm, conservative surgery was indicated, followed by radiotherapy on the breast and the supraclavicular area in the event of lymph node involvement at doses between 50 and 54 Gy, with a boost of 14 to 16 Gy on the tumor bed (standard spreading spread: 1.8–2 Gy per session; 5 sessions / week) associated or not with adjuvant chemotherapy depending on the anatomopathological results.Those larger than 3 cm were often treated by radical Patey surgery followed by radiotherapy of the thoracic wall and the supraclavicular area at a dose of 50–54 Gy, and 6 to 8 courses of chemotherapy as adjuvant function of the anatomopathological report.

In the case of locally advanced tumors (T4), patients benefited from neoadjuvant chemotherapy followed by Patey surgery and locoregional radiotherapy.

The statistical study was carried out by the SPSS statistical computer program. The estimates of overall survival and disease-free survival were carried out according to the Kaplan Meier method.

RESULTS
Epidemiological Criteria
During the study period (2013-2017), the oncology and radiotherapy department of the Mohammed VI CHU in Marrakech admitted 2,207 cases of breast cancer. Among these patients, 318 were aged 40 and under, representing a rate of 14.4% of the total number of patients with breast cancer during this period.

Table-1: Distribution of the annual frequency of breast cancer in our series

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of cases ≤40 years</th>
<th>Number of cases</th>
<th>Percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>47</td>
<td>432</td>
<td>10.87%</td>
</tr>
<tr>
<td>2014</td>
<td>52</td>
<td>407</td>
<td>12.77%</td>
</tr>
<tr>
<td>2015</td>
<td>54</td>
<td>409</td>
<td>13.2%</td>
</tr>
<tr>
<td>2016</td>
<td>90</td>
<td>526</td>
<td>17.11%</td>
</tr>
<tr>
<td>2017</td>
<td>75</td>
<td>434</td>
<td>17.28%</td>
</tr>
<tr>
<td>Total</td>
<td>318</td>
<td>2207</td>
<td>14.4%</td>
</tr>
</tbody>
</table>

The average age of the patients was 34.2 years with extremes of 19 and 40 years. The 36-40 age group was the most affected with a rate of 50%.

As for risk factors; the age of the menarche was specified in 134 patients. 104 of them had a menarche at an age > 12 years or 77.6% of cases, while only 30 patients had their early menarche at an age ≤ 12 years or 22.4% of cases. Contraceptive use was specified in 258 patients. Thus, 136 of them confirmed taking oral contraceptives, or 52.7% of cases, for an average duration of 7 years with extremes of 6 months and 20 years. The age of first pregnancy in non-nulliparous patients (88%) was specified in 96 women. He was 22 years old on average with extremes of 17 and 38 years old. Personal history of fibrocystic mastopathy was found in 5 patients or 1.6%. Among the 318 patients, a family history of breast cancer was found in 42 patients or 13.2% of cases. In addition, we noted 1 case of endometrial cancer, 4 cases of ovarian cancer and 3 cases of cervical cancer.

Clinical Criteria
The delay between the appearance of the first symptoms and the date of the first consultation was specified in 286 patients. Thus, the average time was 7 months with extremes of 1 month and 5 years.

Breast cancer was discovered in 98% of cases by the patient herself by self-examination of a breast
nodule, while only 5 cases were detected during a systematic medical examination, or 2%. Bilateral damage was observed in 8 patients (2.5%). The mean clinical nodule size was 5.5 cm with extremes of 1 cm and 10 cm, fixed in 63 women or 41%. Palpation of the lymph nodes made it possible to objectify the presence of axillary lymphadenopathy in 25% of the cases. The cT2N2M0 stages were predominant (48%).

The ultrasound-mammography couple was performed in all the patients, and showed a predominance of the ACR5 stage. The MRI was performed in a single patient, she objectified a speculated image with calcifications. The multifocalities was observed in 20%.

At the end of the extension assessment, 86 patients were immediately metastatic, i.e. 31% of the cases. The main site of metastasis was bone (43%), followed by the liver (28%), then the lungs and pleura (23%), then the brain (6%).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Number of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Singles (n = 318)</td>
<td>19% (n=62)</td>
</tr>
<tr>
<td>Nulligeste (n = 318)</td>
<td>22% (n=70)</td>
</tr>
<tr>
<td>Menarche less than 12 ans (n=134)</td>
<td>22.4% (n=30)</td>
</tr>
<tr>
<td>Familly history (n=318)</td>
<td>13.2% (n=42)</td>
</tr>
<tr>
<td>Tumor size (n = 318)</td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>17% (n=56)</td>
</tr>
<tr>
<td>T2</td>
<td>45.7% (n=146)</td>
</tr>
<tr>
<td>T3</td>
<td>18.5% (n=58)</td>
</tr>
<tr>
<td>T4</td>
<td>18.5% (n=58)</td>
</tr>
<tr>
<td>Clinical GG (n =318)</td>
<td>25% (n=80)</td>
</tr>
</tbody>
</table>

**Therapeutic Results**

The majority of patients received multimodal treatment combining conservative or radical surgery, radiotherapy and adjuvant or neoadjuvant chemotherapy.

On the therapeutic side, breast surgery was performed on 240 of our patients: it was radical (mastectomy with axillary dissection) in 66% of cases and conservative (tumerectomy with axillary dissection) in 34% of cases.

The sentinel node technique was performed in only one patient, and 2 patients benefited from breast reconstruction. The surgery was performed after neoadjuvant chemotherapy for locally advanced tumors in 56 patients.

In the anatomopathological study, non-specific invasive carcinoma was the most predominant with a rate of 89%, followed by infiltrative lobular carcinoma (CLI) with a rate of 5.66%. Grade SBR II was the most common at 66%, followed by grade SBR III at 30%. These estrogen (ER) and progesterone (RP) receptors were both positive in 65% of the cases, dissociated in 7% and negative in 28%. 35% of all patients had overexpression of the HER2. The tumor emboli were positive in 76% of the cases. Three hundred and eight patients presented healthy margins of excision. 69% had a lymph node invasion 83% presented a capsular breach.

In the adjuvant setting, 191 patients benefited from external radiotherapy, and chemotherapy was indicated in 170 patients, i.e. 61% of the cases, while 20% received it as a neo-adjuvant, based on anthracyclines and taxanes in 6 or 8 courses. Hormone therapy was started in 156 patients; curative in 144 and palliative in the remaining 12, and consisted of administer tamoxifen-type antiestrogens in 142 patients and anti-estrogens with medical castration in 14 cases, with an average duration of taking 14.7 months (1 month and 5 years). Trastuzumab was indicated in 86% of cases.

In our series, the patients were followed until March 2019. The median follow-up was 8.1 months with extremes of 1 month and 7 years 3 months. 118 patients (37% of all cases) had a relapse of their disease in the form of a locoregional recurrence (49%), metastatic dissemination (51%) or both. The mean time to relapse was 9.5 months. The number of patients who died was 82 or 25.7% of all patients, with an average survival time of 2.6 years and extremes ranging from 2 years to 4 years. 91 cases or 28.6% lost to follow-up and 145 are still alive (45.6%).
Table 3: Pathological characteristics of the patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Number of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histological type (n = 318)</td>
<td></td>
</tr>
<tr>
<td>Ductal carcinoma</td>
<td>89% (n=283)</td>
</tr>
<tr>
<td>Lobular carcinoma</td>
<td>6% (n=19)</td>
</tr>
<tr>
<td>Others</td>
<td>5% (n=16)</td>
</tr>
<tr>
<td>Nuclear grades (n = 318)</td>
<td></td>
</tr>
<tr>
<td>Grade I</td>
<td>4% (n=13)</td>
</tr>
<tr>
<td>Grade II</td>
<td>66% (n=210)</td>
</tr>
<tr>
<td>Grade III</td>
<td>30% (n=95)</td>
</tr>
<tr>
<td>Hormones receptors (n = 318)</td>
<td></td>
</tr>
<tr>
<td>RE+ RP-</td>
<td>3% (n=10)</td>
</tr>
<tr>
<td>RE- RP+</td>
<td>4% (n=13)</td>
</tr>
<tr>
<td>RE- RP+</td>
<td>28% (n=90)</td>
</tr>
<tr>
<td>RE+ RP+</td>
<td>65% (205)</td>
</tr>
<tr>
<td>Non précisé</td>
<td></td>
</tr>
<tr>
<td>Overexpression HER2 (n=274)</td>
<td></td>
</tr>
<tr>
<td>HER2+</td>
<td>65% (n=178)</td>
</tr>
<tr>
<td>HER2-</td>
<td>35% (n=96)</td>
</tr>
<tr>
<td>Tumor embolis (n=200)</td>
<td>76% (152)</td>
</tr>
<tr>
<td>Intraductal Component (n=110)</td>
<td>75% (n=82)</td>
</tr>
</tbody>
</table>

**DISCUSSION**

The age limit for defining breast cancer in young women is controversial; several series have defined a “young” woman as corresponding to a woman under 30, 35, 40, 45 years or simply not menopausal [1-4]. In our study, and as for the majority of the authors, the age limit of 40 years was fixed.

According to the GLOBOCAN 2018 database, which groups the incidences and mortality in 185 countries of 36 types of cancer; the most common type of cancer in women, in all regions, was breast cancer, accounting for 22 to 28% of new cases [5].

Nationally, 35.8% of cases are recorded in GRAND CASABLANCA CANCER REGISTER. The incidence of breast cancer in women increased continuously with age; a peak was recorded for the age class 55-59 reaching 197.3 per 100,000 women [6]; which is consistent with the data from our study where 85.6% of women with breast cancer were over 40 years of age; while patients aged 40 and under represented only 14.4%.

The average age of diagnosis of breast cancer was 34.2 years with extremes of 19 and 40 years, which is consistent with the data in the literature, or this average varies between 31 and 32 years [12]. The lowest age reported in the literature is 14 years [1].

The family history of breast cancer seems to be the essential risk factor for developing breast cancer at a young age [13, 14] indeed, it is, here, the transmission of a genetic mutation mainly at the level BRCA1 and BRCA2 genes responsible for the development of cancer from one generation to another [15]. In our study, the family history of breast cancer was found in 13.2% of cases, which is consistent with the data in the literature; moreover, in our series, no patient benefited from the search for the BRCA1 and BRCA2 genes seen on high cost. Other risk factors linked to the female genital life have been retained, mainly, early menarche and nulliparity [12, 16] because these women have been exposed to estrogen secretion for longer. In our study, the early menarche was objectified in 22.4% of the cases, the nulliparity in 22% which agrees with the other series.

In our series; clinical criteria did not present any particularity in young women, breast nodule was the most frequent reason for consultation with a rate of 87.7%, which corresponds to other studies. The discovery is often late and the tumor size is larger compared to older women. The average clinical nodule size in our series was 5.5 cm. Palpation of the lymph nodes made it possible to objectify the presence of axillary lymphadenopathy in 25% of the cases; C2n2M0 stages were predominant in 48% of the cases, which joins all the published series. The authors report a T2 frequency of 40% to 50% of cases [3, 4, 17, 10],
and clinical lymph node involvement varied between 50 and 75% [1, 4, 10].

Exploring breast cancer is more difficult in young women [18]; Mammography was classically unsuccessful and must be coupled with Breast ultrasound according to several authors [3, 19] MRI is very important in this population of young women allowing a correct estimate of multifocal, bilateral cancers and recurrences [20]. This investigation was not carried out in our population due to lack of resources, and half of the patients initially presented ACR 5 lesions on mammography.

The diagnostic certainty of breast cancer is provided by histological examination. The distribution of histological types in young women does not differ from that observed in elderly women. Most authors [21] agree on the predominance of invasive carcinomas in young women as well as in elderly women. In our study infiltrating ductal carcinoma predominates with a rate of 89%, joining the other series of Bouzid with a rate of 95% [10]; of boufettal with a rate of 73% [4], of C. Fleurier [11] with a rate of 91%.

The high histo-prognostic grade and the high level of negative hormone receptors explain the aggressiveness of cancer in young women. According to the prospective American observational study POSH [22] evaluating the anatomopathological characteristics of 2,956 cases of breast cancer in women aged under 40, the study objectified the following characteristics: 58.9% of grade III tumors, a third of negative estrogen receptors and a quarter of Her2 overexpression which does not correspond to the results of our study where grade II was the most frequent with a rate of 66%; estrogen (ER) and progesterone (RP) receptors were both positive in 65% of the cases.

Many authors agree that lymph node invasion is more frequently observed in young women and is around 50% in the majority of series [3, 10, 11, 22]. We found a rate of 69%, close to the bouzid series [10].

The indications for surgical treatment in young women do not differ from those in older women. VAN DE VELDE [23] and GENEVIEVE [24], compared radical surgery to conservative surgery in young women and found that not only the recurrence rate was three times lower in women treated with mastectomy, but that the survival rate was significantly higher in this category of patients. This is linked to unfavorable differences in stage and tumor biology in young women according to Matthews et al., [25]; but this should not lead to the exclusion of conservative surgery in this population. In our series 41% recurred after conservative treatment and 31% after a patty.

The main aim of radiotherapy is local control of the tumor. It reduces the risk of locoregional relapse by 70% and improves overall survival [26, 27]. Radiation therapy is systematic after conservative surgery, its beneficial effect has been mainly observed in young women [28]. Parietal irradiation after radical surgery is recommended for tumors larger than 20mm (T2) in young women after sufficient negative axillary lymph node dissection [29].

The interest of chemotherapy is currently demonstrated in the treatment of breast cancer in young women; regardless of lymph node status and stage of the disease. An annual reduction of 29% in the risk of general mortality in patients under 40 was shown in the Oxford meta-analysis [30]. The efficacy of adjuvant HTC is greater in premenopausal women, hence the more frequent use of adjuvant chemotherapy in young women [31], in our series 61% of our patients received adjuvant chemotherapy. However, the advantage of herceptin in the adjuvant situation has been demonstrated for HER-2 + patients regardless of age [32]. Early menopause can be induced by chemotherapy. This risk must be explained to patients wishing to have pregnancies.

The hormone therapy currently recommended in young women is tamoxifen alone or associated with ovarian suppression; Anti-aromataxes have no place. Tamoxifen given to young women prolongs survival and delays relapse, although its benefit is not as great as that obtained in postmenopausal women [33].

Local recurrences and metastases occur more often in young women than in older women [4, 34]. According to Rochefordiere et al., after five years, the relative risk of recurrence decreases less quickly in young women [4, 35].

In our series, locoregional relapses were 18% joining most of the Maghreb and Western series, and metastatic relapses were 19%, a rate which joined the boufettal and flower series and which is lower than the other series [4, 10, 11].

The 5-year survival rate is even lower when the age is young. The MOLNAR series [36] has objectified that survival in young women is much lower than in older patients. Thus, other series [36, 37] have found a correlation between young age and low survival rate.

In our series, the overall 3-year survival was 68% and the relapse-free survival at 59%, which joins the Maghreb series: bouzid, and Boufettal [4, 10].

The factors most often retained in the literature as poor prognosis, are identical regardless of the age of diagnosis including, tumor size; lymph node involvement, histoprognostic stage, hormone receptors, intracanal component (CIC) greater than 25%. In young women, the poor prognosis for breast cancer is the
advanced stage of diagnosis [38]. In our series, the presence of vascular emboli was identified in 76% of patients and CIC greater than 25% in 75% of cases.

CONCLUSION

Young age is often associated with anatomical-clinical and progressive parameters of poor prognosis. It is therefore necessary to adopt multidisciplinary management. It would be interesting to reconsider the indications for screening in our country as they do not include young women, as well as to encourage oncogenetic consultations in women at risk.

REFERENCES


